OraSure Sees Profitability In 2002 With OraQuick, UPlink Introductions
This article was originally published in The Gray Sheet
Executive SummaryOraSure Technologies expects FDA approvals of its UPlink drugs-of-abuse test and OraQuick rapid HIV assay to help the firm reach profitability this year and grow revenues 30% over 2001
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.